August 11th, 2010 - A partnership between a major biopharmaceutical company in the U.K. and researchers at Cardiff University in Wales will evaluate the drug TroVax for use in treating mesothelioma.
According to RTT News, Oxford BioMedica will team up with cancer immunologists led by Zsuzsanna Tabi at Cardiff University and oncologist Dr. Jason Lester of Velindre Cancer Center in Cardiff.
In the study, the drug will be used in combination with first-line chemotherapy drugs Alimta and cisplatin, both commonly used therapies for mesothelioma. The disease, a rare form of cancer, is linked to previous exposure to asbestos.
The research is funded by the June Hancock Mesothelioma Research Fund. Patient recruitment for Phase I and II of the study is expected to start later this year, the news website reported.
TroVax, a therapeutic cancer vaccine that stimulates an anti-cancer immune response, also recently received approval from the U.S. Food and Drug Administration to start Phase II of a study of the drug in use against hormone refractory prostate cancer, a form of the disease that develops when hormone therapy fails to stop its growth. About 80 patients are expected to be enrolled in five study sites across the U.S. The drug will be tested in use with the chemotherapy drug Docetaxel starting later this year.ADNFCR-3137-ID-19923921-ADNFCR
0 Comments:
Post a Comment